By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    photo of hands with blue veins
    8 Proven Tips on Finding Difficult Veins
    November 12, 2021
    tips for getting over the pandemic blues
    4 Proven Ways to Get Over the Pandemic Blues
    February 22, 2022
    medical industry innovations
    How is CNC Machining Transforming the Medical Industry?
    June 2, 2022
    Latest News
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Doctors on Google: Manhattan Research Survey 2012
    July 23, 2012
    HealthCare’s Need for Transparency Goes Far Beyond Pricing
    December 10, 2012
    Medicare Payments to Providers Are Carved, Sliced and Chopped by Sequestration
    March 25, 2013
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: New Test Claims It Can Tell If You Will Develop Alzheimer’s
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > New Test Claims It Can Tell If You Will Develop Alzheimer’s
BusinessMedical InnovationsTechnology

New Test Claims It Can Tell If You Will Develop Alzheimer’s

Nicole Fisher
Last updated: February 19, 2018 8:09 pm
Nicole Fisher
Share
6 Min Read
AD costs 2050.pptx
SHARE

 

Alzheimer’s disease is the most expensive condition in the nation. The estimated cost of care for Alzheimer’s disease in the US alone exceeded $214 billion in 2014, with nearly one in every five dollars spent by Medicare on dementia.  Further, future cost estimates from the Alzheimer’s Association predict that by 2050 the disease will cost $1.2 trillion annually. The disease currently affects five million people in the US, and expected to grow to 16 million by 2050, afflicting one in nine people over the age 65, and one in three people over the age of 85. With patients, care providers, researchers and policymakers desperate for a definitive test, the world is one step closer to having results.

But would you want to know if you are going to develop – or are already in pre-symptomatic early stages of – Alzheimer’s disease? When there is currently no known cure and only marginal progress in symptomatic treatments, what good or harm comes from knowing? This hypothetical is one step closer to being your reality. Last week, Congressman Chaka Fattah (D-PA), architect of the Fattah Neuroscience Initiative, met with Amarantus Bioscience Holdings, a biotech company that is developing a set of neurology-focused diagnostic products, to discuss the importance of genomic testing for Alzheimer’s disease, the growing need of more federal funding for Alzheimer’s research and the company’s new Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic test that it claims uses biomarkers to identify at-risk individuals for Alzheimer’s.

According to Dr. Howard Federoff, Executive Vice President for Health Sciences and Executive Dean of Georgetown University Medical Center, he is “exited there is a means by which we can test people. The excitement falls on the fact that we have failed many times in the past and spent a lot of money, as has everyone in this field. Now we can test preclinically as to enable people to take preventative measures or in the future cure it. Additionally, because a preexisting condition no longer means that you can be precluded from long-term care and life insurance, financial planning is now possible for individuals, families, employers and societies.”AD costs 2050.pptxIs Ignorance Bliss?

More Read

information addiction
The Information Junkies in Your Support Group
Asthma Medical Home at Boston Children’s Hospital Wins Innovation Challenge
Memorial Sloan-Kettering Says No to Cancer Drug Zaltrap for Colorectal Cancer-Avastin Works Just As Well and the Cost is Half
Reining in Avoidable Readmissions
Company Seeking Type 1 Diabetes Early Detection Tool

The dichotomy of those who want to know and those who do not is separated by a deep chasm in beliefs, and could forever alter the way individuals, families and wealth managers prepare for disease, as well as how insurers and care providers pay for and provide care. While genetic tests are presently able to determine about 4,000 diseases and disorders, the breakthrough of predicting Alzheimer’s disease could vastly change the behaviors and costs to society, actually bending the cost curve health experts so often talk about as necessary for economic stability. Until now, official diagnosis of the disease has been reserved for the autopsy table, an unacceptable situation.

In January, Amarantus reported positive top-line results of its LymPro Test®blood diagnostic for Alzheimer’s disease. The Company also entered into an exclusive option agreement with Georgetown University (GU) to commercialize sets of blood-based biomarkers for Alzheimer’s disease. The Company has said it is positioning itself to capture the lion’s share of the Alzheimer’s blood test market – eventually worth an estimated $3 billion.

But how will individuals react? How about the care provider and insurance markets? When there is presently no cure, it is expected that individuals and families will be torn on the decision to test.  In contrast, it seems inevitable that employers, health officials and insurers will want to know the future demands, needs and composition of their populations.blood-test

A Game-Changing Blood Test 

Blood-based biomarkers of preclinical disease will certainly be critical for preventative or disease modifying advances in the coming years. However, to date, these biomarkers for early disease detection have not been accurate, are extremely expensive, time consuming and invasive. However, Dr. Federoff claims that their lipid approach has revealed, “ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer’s disease within a 2–3 year timeframe with over 90% accuracy. More exciting, we currently have, under review, the metabolomics data that could go even further, showing 99% accuracy measuring 17 lipids.”

The group’s exosome work was recently published in an Alzheimer’s Association’s publication providing a second important modality to GU’s conceptual understanding of the disease. According to Dr. Federoff, this “secondary prevention is a whole new kind of clinical trial,” that cannot be ignored much longer. Congressman Fattah, who has led Congress in efforts to increase public funding for brain research was also named as one of four co-chairs of the House Alzheimer’s Disease Caucus last week, has also committed to using information like this to, “advocate for policies, research, and funding that will advance our efforts to fight Alzheimer’s disease.”

While LymPro® is not ready for the shelves of CVS or Walgreen’s, it may not be long before in clinic and in home testing is available to consumers. Without a cure or highly effective symptomatic treatments to go hand-in-hand with the blood test, the risk and reward of such a test will certainly take a toll on individuals, families, health care markets and communities.

Amarantus says it will publish data from its studies in peer-reviewed journals as well as present them at various scientific conferences throughout 2015.

TAGGED:Alzheimers
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Clinical Expertise
Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
Health care
May 18, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Health
May 15, 2025
Learn how to Renew your Medical Card in West Virginia
Learn how to Renew your Medical Card in West Virginia
Health
May 15, 2025
Dr. Klaus Rentrop Shares Acute Myocardial Infarction heart treatment
Dr. Klaus Rentrop Shares Acute Myocardial Infarction
Cardiology
May 13, 2025

You Might also Like

Calling for More Than an Ounce of Prevention

November 1, 2012
Customer
BusinesseHealthSocial Media

Beyond the C-Suite: 3 Ways to Build Customer Focus

April 21, 2014
organizing your psychotherapy practice
Business

Extremely Important Organization Tips for Psychotherapists

April 19, 2021
mhealth around the globe
eHealthMedical DevicesMedical InnovationsMobile HealthTechnology

Mobile Health Around the Globe: Gene-RADAR Can Test for Viruses in Remote Locations

October 28, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?